TMO.NEO Thermo Fisher CDR (CAD Hedged)
- Market cap
- CAD 347B
- P/E
- 38.0x
- P/B
- 4.36x
- ROE
- 12.9%
- Dividend yield
- 0.30%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is TMO.NEO undervalued?
Graham numberTMO.NEO trades 171.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Thermo Fisher CDR (CAD Hedged) fundamental analysis
8 of 22 checks passedROE 1/2
Moderate return on equity (12.9%), between 10% and 20%.
ROA 1/1
Return on assets (6.0%) is above the industry median (5.5%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (7.1%) is below the industry median (33.8%).
Revenue Growth 0/2
Revenue shrank 0.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (74.4%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 5.8x against interest expense, well covered.
PE vs Market 0/1
PE (38.7x) is above the market median (20.3x).
PE vs Industry 0/1
PE (38.7x) is above the industry median (20.3x).
PBV 0/1
Price to book (4.4x) is above the industry median (2.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 171.7, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.2%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 9.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Thermo Fisher CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Thermo Fisher CDR (CAD Hedged)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments seg…
Full company profileThermo Fisher CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Thermo Fisher CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 39.2B | 44.9B | 42.9B | 42.9B | 44.6B | 46.0B |
| Gross Profit | 19.6B | 19.0B | 17.1B | 17.7B | 18.2B | 18.6B |
| Operating Income | 10.2B | 8.51B | 7.32B | 7.72B | 8.11B | 8.20B |
| EBITDA | - | 11.9B | 11.1B | 11.5B | 11.5B | 11.9B |
| Net Income | 7.73B | 6.95B | 6.00B | 6.34B | 6.70B | 6.77B |
| EPS | 20 | 18 | 16 | 17 | 18 | 18 |
| Balance Sheet | ||||||
| Total Assets | 95.1B | 97.2B | 98.7B | 97.3B | 110B | 113B |
| Total Liabilities | 54.1B | 53.0B | 51.9B | 47.6B | 56.8B | 60.4B |
| Shareholders' Equity | 40.8B | 44.0B | 46.7B | 49.6B | 53.4B | 52.7B |
| Cash & Short-term Investments | 4.48B | 8.52B | 8.08B | 4.01B | 9.85B | 4.06B |
| Cash Flow | ||||||
| Operating Cash Flow | 9.31B | 9.15B | 8.41B | 8.67B | 7.82B | 6.63B |
| Capital Expenditure | 2.52B | 2.24B | 1.48B | 1.40B | 1.53B | 1.65B |
| Free Cash Flow | 6.79B | 6.91B | 6.93B | 7.27B | 6.29B | 4.98B |
| Ratios | ||||||
| ROE | 18.9% | 15.8% | 12.8% | 12.8% | 12.6% | 12.9% |
| ROA | 8.1% | 7.2% | 6.1% | 6.5% | 6.1% | 6.0% |
| Net Profit Margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.0% | 14.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Thermo Fisher CDR (CAD Hedged) dividends
- Dividend yield
- 0.30%
- Forward dividend
- 0.06 CAD
- Payout ratio
- 9.5%
- Ex-dividend date
- Dec 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 636M | 1.69 | 9.5% |
| 2024 | USD 583M | 1.53 | 9.2% |
| 2023 | USD 523M | 1.35 | 8.7% |
| 2022 | USD 455M | 1.17 | 6.5% |
| 2021 | USD 395M | 1.00 | 5.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Thermo Fisher CDR (CAD Hedged)
Ownership data of Thermo Fisher CDR (CAD Hedged) is not available yet.
Thermo Fisher CDR (CAD Hedged) company profile
- Company name
- Thermo Fisher CDR (CAD Hedged)
- Ticker
- TMO.NEO
- ISIN
- CA88355G1000
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 125,000
- Fiscal year end
- December
- Address
- 168 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 781 622 1000
- Website
- thermofisher.com
About Thermo Fisher CDR (CAD Hedged)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Thermo Fisher CDR (CAD Hedged) management
10- Mr. Marc N. CasperChairman, President & CEO · born 1968
- Mr. Stephen WilliamsonSenior VP & CFO · born 1967
- Mr. Michel LagardeExecutive VP & COO · born 1975
- Mr. Frederick M. LoweryExecutive VP and President of Laboratory Product & BioProduction · born 1971
- Mr. Gianluca PettitiExecutive VP and President of Life Science, Diagnostics & Applied · born 1979
- Mr. Joseph R. HolmesVP & Chief Accounting Officer · born 1979
- Mr. Ryan J. SnyderSenior VP & Chief Information Officer
- Dr. Karen E. Nelson Ph.D.Chief Scientific Officer
- Mr. Rafael TejadaVice President of Investor Relations
- Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel